Systemic hypersensitivity to fosaprepitant - A report of two cases

被引：3

作者：

Baxley, Allison ^{[1
]}

Lee, Zoe ^{[2
]}

Medina, Patrick ^{[2
]}

机构：

[1] Stephenson Canc Ctr, 800 NE 10th St,Suite 3030, Oklahoma City, OK USA

[2] Univ Oklahoma, Coll Pharm, Oklahoma City, OK USA

来源：

JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2018年 / 24卷 / 01期

关键词：

Fosaprepitant; infusion reaction; hypersensitivity; anaphylaxis; CHEMOTHERAPY; APREPITANT; CISPLATIN; EFFICACY; SAFETY;

D O I：

10.1177/1078155216680118

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fosaprepitant is a widely administered antiemetic used mainly for moderately to highly emetogenic chemotherapy. Local injection site reactions are the most common type of infusion reaction reported from fosaprepitant. At our institution, two separate patients have experienced systemic hypersensitivity reactions to their infusions of fosaprepitant. We report a review of the literature and the details of these reactions.

引用

页码：76 / 78

页数：3

共 7 条

[1] Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety [J].

Aapro, Matti ;

Carides, Alexandra ;

Rapoport, Bernardo L. ;

Schmoll, Hans-Joachim ;

Zhang, Li ;

Warr, David .

ONCOLOGIST, 2015, 20 (04) :450-458

[2] Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol-EASE [J].

Grunberg, Steven ;

Chua, Daniel ;

Maru, Anish ;

Dinis, Jose ;

DeVandry, Suzanne ;

Boice, Judith A. ;

Hardwick, James S. ;

Beckford, Elizabeth ;

Taylor, Arlene ;

Carides, Alexandra ;

Roila, Fausto ;

Herrstedt, Jorn .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) :1495-1501

[3] Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects [J].

Lasseter, Kenneth C. ;

Gambale, Jay ;

Fin, Bo ;

Bergman, Art ;

Constanzer, Marvin ;

Dru, James ;

Han, Tae H. ;

Majumdar, Anup ;

Evans, Judith K. ;

Murphy, M. Gail .

JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (07) :834-840

[4]

Merck & Co Inc, 2008, EM INJ PACK INS

[5]

National Comprehensive Cancer Network, ANT VERS 2

[6] Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial [J].

Saito, H. ;

Yoshizawa, H. ;

Yoshimori, K. ;

Katakami, N. ;

Katsumata, N. ;

Kawahara, M. ;

Eguchi, K. .

ANNALS OF ONCOLOGY, 2013, 24 (04) :1067-1073

[7] Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas [J].

Tsukahara, Kiyoaki ;

Nakamura, Kazuhiro ;

Motohashi, Ray ;

Sato, Hiroki ;

Endo, Minoru ;

Katsube, Yasuaki ;

Ueda, Yuri ;

Suzuki, Mamoru .

ACTA OTO-LARYNGOLOGICA, 2014, 134 (11) :1198-1204

← 1 →